| scholarly article | Q13442814 |
| P50 | author | Jonathan N Tobin | Q107410611 |
| P2093 | author name string | Chaim Putterman | |
| Anna Broder | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| Evidence-based management of thrombosis in the antiphospholipid antibody syndrome | Q28165262 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience | Q33572764 | ||
| Epidemiology of the antiphospholipid antibody syndrome | Q33916234 | ||
| Pathogenic mechanisms mediating antiphospholipid syndrome | Q34404108 | ||
| Antiphospholipid syndrome: a comprehensive review of a complex and multisystemic disease. | Q35004519 | ||
| Antiphospholipid antibodies and thrombosis: strength of association | Q35134974 | ||
| Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. | Q35176607 | ||
| Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study | Q35213010 | ||
| The role of antiphospholipid antibodies in stroke. | Q35966558 | ||
| New approaches for managing antiphospholipid syndrome | Q37404485 | ||
| An update on the role of markers of inflammation in atherosclerosis | Q37662089 | ||
| Towards evidence-based treatment of thrombotic antiphospholipid syndrome | Q37721614 | ||
| Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand? | Q37812011 | ||
| A review of goodness of fit statistics for use in the development of logistic regression models | Q40338804 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model | Q44652593 | ||
| Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells | Q45033718 | ||
| Antiphospholipid antibodies and venous thromboembolism | Q54157484 | ||
| Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. | Q55547645 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS | Q79358178 | ||
| Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease | Q81033955 | ||
| Antiphospholipid antibodies in patients with coronary artery disease: new cardiac risk factors? | Q81349131 | ||
| Diverse effects of statins on endothelial cells? | Q81402632 | ||
| Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study | Q82045296 | ||
| Antiphospholipid syndrome | Q83045722 | ||
| Antiphospholipid syndrome: critical analysis of the diagnostic path | Q83954306 | ||
| Risky business: the interpretation, use, and abuse of antiphospholipid antibody tests in clinical practice | Q83954315 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| endothelium | Q111140 | ||
| thrombosis | Q261327 | ||
| P304 | page(s) | 551-556 | |
| P577 | publication date | 2012-03-03 | |
| P1433 | published in | Journal of Clinical Pathology | Q6294965 |
| P1476 | title | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study | |
| P478 | volume | 65 |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q38078691 | Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases |
| Q36314964 | Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome |
| Q37522782 | Improving outcomes in patients with lupus and end-stage renal disease |
Search more.